patent.fyi
Applications  /  US 2026/0355101
United States Patent Application Publication

US 2026/0355101 A1

Published
Nov 12, 2026
Filed
May 1, 2026
Earliest date on the face
May 12, 2025
Classification
A61K 8/97
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Vesicles from carrot membrane lipids

What ifWhat if the plant-derived vesicles were assembled from extracted carrot membrane lipids?
Claim language“isolating exosomes from cells”

Extract phospholipids from carrot tissue and evaporate the extraction solvent to form a lipid film. Hydrate the film in an aqueous buffer and pass the dispersion through a membrane with 100 nm pores to size the reconstituted vesicles.

1.2Cargo loading through niosomes

What ifWhat if the unfused niosomes carried the added bioactive substances into the fusion step?
Claim language“into the vegan exosomes”

Dissolve niacinamide in the aqueous phase and alpha-tocopherol in the surfactant phase during niosome preparation. Remove free solute by size-exclusion chromatography, then combine the loaded niosomes with the plant vesicles for fusion.

1.3Niosome sizing by membrane extrusion

What ifWhat if membrane extrusion set the niosome size after thin-film hydration?
Claim language“performing high-pressure homogenization”

Cast a film of sorbitan monostearate and plant-derived cholesterol, then hydrate it with warm water to form a vesicle dispersion. Pass the dispersion through 200 nm and then 100 nm track-etched membranes using a bench-top extruder.

1.3Sterol-free niosomes from surfactant

What ifWhat if a long-chain nonionic surfactant formed niosomes in water without a separate stabilizer?
Claim language“a stabilizer, and a solvent”

Disperse sorbitan monostearate in water above its chain-melting transition and size the dispersion by high-pressure homogenization. Cool the dispersion so the saturated hydrocarbon chains pack into an ordered bilayer.

1.4Fusion by membrane coextrusion

What ifWhat if repeated passage through a porous membrane fused the two vesicle populations?
Claim language“by ultrasonically treating”

Mix the loaded plant vesicles with the niosomes and pass the mixture repeatedly through a track-etched membrane while the surfactant bilayers are fluid. Confinement in the pores deforms the vesicles, brings their membranes into contact, and promotes rupture and resealing into mixed vesicles.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Antioxidant coating for paper packaging

Plant-derived vesicles loaded with tocopherol and ferulic acid are fused with niosomes by ultrasound. The fused suspension is blended into an aqueous cellulose coating and applied to the inward-facing side of paperboard with a metering rod. Low-temperature air drying forms a film that holds the vesicles at the packaging surface.

Component substitution

Niosome sizing by membrane extrusion

Hydration of a nonionic surfactant and a membrane stabilizer in an aqueous buffer produces a coarse niosome suspension. A piston extruder passes the suspension through a 400 nm polycarbonate membrane, followed by a 200 nm membrane, in place of high-pressure homogenization. The sized niosomes are mixed with loaded plant-derived vesicles and sonicated to fuse the membranes.

Parameter or scale variation

Pulsed sonication with active cooling

A jacketed 50 mL vessel holds 25 mL of loaded plant-derived vesicles mixed with preformed niosomes. A 20 kHz immersion probe applies ultrasound in cycles of 2 seconds on and 8 seconds off over 5 minutes, for a total of 60 seconds of active sonication. Coolant circulates through the jacket to hold the suspension at 10 to 15 °C during membrane fusion.

Combination with existing systems

Vesicle incorporation into a hydrogel patch

A laminate patch combines a flexible backing, an alginate hydrogel layer, and a removable liner. An aqueous suspension of fused plant-derived vesicles and niosomes is mixed into the alginate before casting, and an aqueous calcium salt crosslinks the cast layer. The hydrated layer holds the vesicles against the skin after liner removal and allows released cargo to diffuse through the gel.

Tangential flow cleanup after fusion

A tangential flow filtration loop connects the sonicated suspension reservoir to a hollow-fiber membrane module and returns the retentate to the reservoir. A membrane selected to retain the fused vesicles passes dissolved, unassociated low-molecular-weight cargo into the permeate. Fresh buffer enters the reservoir at the permeate removal rate during washing, and the retained dispersion is collected for formulation.

Automated or data-driven variant

Temperature feedback during ultrasonic fusion

A temperature probe immersed in the mixed suspension sends readings to a programmable controller during ultrasonic fusion. The controller delivers short ultrasound bursts, pauses when the suspension reaches an upper temperature setpoint, and resumes after the cooling jacket returns it to a lower setpoint. The controller integrates measured power over active sonication time and ends the run at a preset energy per unit volume.

Specific version of a part

Multilamellar hybrid vesicles

Dry a concentrated hybrid-vesicle dispersion and rehydrate it gradually under gentle agitation to form multilamellar vesicles. The stacked bilayers retain lipid-soluble cargo in the membranes and enclose water-soluble cargo in the aqueous spaces between them.

Vesicles from leaf apoplastic fluid

Collect apoplastic wash fluid from leaves by vacuum infiltration with an isotonic buffer followed by low-speed centrifugation. Clarify the collected fluid by differential centrifugation and concentrate the extracellular vesicles by ultrafiltration.

Loading niacinamide and tocopherol

Suspend the isolated plant vesicles in a niacinamide solution and apply freeze-thaw cycles to allow aqueous solute to enter as the membranes reseal. Incubate the vesicles with alpha-tocopherol delivered in a small volume of ethanol so it partitions into the bilayer, then remove free material by size-exclusion chromatography.

Homogenized sorbitan monostearate niosomes

Mix sorbitan monostearate and plant-derived cholesterol at a 2:1 molar ratio in ethanol, evaporate the solvent, and hydrate the resulting film with water. Pass the warm vesicle dispersion three times through a high-pressure homogenizer at 600 bar.

Pulsed probe sonication for fusion

Combine the loaded plant vesicles and preformed niosomes in a buffered aqueous dispersion. Apply a 20 kHz probe in 5-second pulses separated by 10-second cooling intervals to bring the membranes into contact and promote lipid mixing.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2007/0172520 A1
Published
Jul 26, 2007
Filed
Nov 20, 2006
Class
A61K 39/395
Document BUS 2022/0288146 A1
Published
Sep 15, 2022
Filed
Jul 30, 2020
Class
A61K 36/185
Claim 1
Document A
Document B
1.1(S10) preparing vegan exosomes by isolating exosomes from cells derived from plants or microorganisms, excluding animal cells;
Exosomes are vesicles, which are released by many organisms from prokaryotes to high eukaryotes and plants, and which contain lipid bilayer vesicles of different sizes [10].
B · US 2022/0288146 A1 · ¶ 6
1.2(S20) inserting multiple bioactive substances into the vegan exosomes of step (S10);
The constituted niosomal vesicle can advantageously include a bioactive agent thus providing a delivery agent for the targeted delivery of the bioactive compound.
A · US 2007/0172520 A1 · ¶ 13
The therapeutic agent-loaded exosomes of the said invention are used for treating or lessening the severity of various diseases, wherein one of these diseases is amyotrophic lateral sclerosis (ALS). The therapeutic effect is not provided by the exosomes but by the drug that they carry.
B · US 2022/0288146 A1 · ¶ 12
1.3(S30) preparing niosomes by mixing a non-ionic surfactant, a stabilizer, and a solvent, and performing high-pressure homogenization; and
Niosomes were synthesized by classical thin-film hydration methods (Yoshioka T, Stemberg B, Florence A T: Preparation And Properties Of Vesicles (Niosomes) Of Sorbitan Monoesters (Span-20, Span-40, Span-60 And Span-80) And A Sorbitan Triester (Span-85). International Journal Of Pharmaceutics 1994;105:1-6) with a mixture of biocompatible sorbitan ester surfactants and cholesterol using both agitation and sonication during the hydration phase.
A · US 2007/0172520 A1 · ¶ 49
1.4(S40) fusing the vegan exosomes and the niosomes by ultrasonically treating the vegan exosomes into which the multiple bioactive substances are inserted in step (S20) and the niosomes of step (S30),
1.5wherein the hybrid nanocomposite forms a bilayer or a trilayer by irregularly arranging a portion of a bilayer constituting the vegan exosomes and a portion of a bilayer constituting the niosomes, and the multiple bioactive substances inserted into the vegan exosomes are positioned on or attached to a surface of the hybrid nanocomposite, between membranes of the hybrid nanocomposite, or inside the hybrid nanocomposite.

An empty cell means only that no passage was reproduced there.

Statements in these documents
Normal administration of drugs or therapeutic agents does not allow for concentrated accumulation of drug at diseased sites due to an essentially uniform distribution of drug throughout the body.
A · US 2007/0172520 A1 · ¶ 3
Niosomal encapsulation reduces toxicity of drugs in many different applications and therapies.
A · US 2007/0172520 A1 · ¶ 6
The present invention relates to use of plant exosomes for reducing the protein aggregates formed in cells and the damage they cause to the cell.
B · US 2022/0288146 A1 · ¶ 1
The mutant SOD1 produced as a result of a mutation folds differently (misfolds) from its healthy form, causing protein aggregates that result in death of neurons [4, 5, 6].
B · US 2022/0288146 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0355101 A1, claim 1, first published 2026-11-19T07:53:10-05:00, https://patent.fyi/US20260355101/, SHA-256 ddb601b42fe93150474d320bc67496841f55eb5d38afa2f042eb657d1d47336c
First published
Permanent addresshttps://patent.fyi/US20260355101/
Content fingerprint (SHA-256)ddb601b42fe93150474d320bc67496841f55eb5d38afa2f042eb657d1d47336c
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi